GOut TrEatment STrategy (GO TEST) FINALE study, a multicentre pragmatic randomized superiority trial of continuation versus cessation of urate lowering therapies in gout in remission.

Sint Maartenskliniek, Nijmegen0 个研究点目标入组 310 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•- Patients with clinical diagnosis of gout and/or fulfilling the 2015 ACR-EULAR gout criteria - Use of ULT (allopurinol, benzbromarone and/or febuxostat) - Achieved remission for = 12 months based on adapted preliminary gout remission criteria (29). o Free of flares and/or clinically apparent tophi during the last 12 months o Serum urate =0.36 mmol/l at baseline and all values in the last 12 months should not be >0.36 mmol/l o Pain due to gout <2 using a 10-point Likert-type scale at baseline o Patient global assessment of gout disease activity <2 using a 10-point Likert-type scale at baseline - Age =18 years and mentally competent - Signed written informed consent

•- Not being able to speak, read or write Dutch well enough - No ability to measure the outcome of the study in the participant (e.g. life expectancy <2 years, planned relocation out of reach of study center) - A strong contra-indication for glucocorticoids, NSAIDs AND colchicine, as this hampers flare treatment - Use of ULT (also) for any other indication than gout (for example nephrolithiasis) - Currently taking regular glucocorticoids, and/or colchicine, and/or interleukin-1 inhibitors for any diagnosis and/or the use of regular NSAID intake for gout activity - A history of myocardial infarction or stroke in the past six months and/or congestive heart failure NYHA class III or IV

发起方

Sint Maartenskliniek, Nijmegen